Halozyme Therapeutics exotic insider transaction detected
| By Randal Kirk | Macroaxis Story |
Filed transaction by Halozyme Therapeutics Inc director. Unconventional Insider trading
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Transaction by Randal Kirk
How important is Halozyme Therapeutics's Liquidity
Halozyme Therapeutics financial leverage refers to using borrowed capital as a funding source to finance Halozyme Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Halozyme Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Halozyme Therapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Halozyme Therapeutics' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Halozyme Therapeutics's total debt and its cash.
Halozyme Therapeutics Gross Profit
Halozyme Therapeutics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Halozyme Therapeutics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Halozyme Therapeutics Gross Profit growth over the last 10 years. Please check Halozyme Therapeutics' gross profit and other fundamental indicators for more details.
An Additional Perspective On Halozyme Therapeutics
Halozyme Therapeutics insider trading alert for general transaction of common stock by Randal Kirk, the corporate stakeholder, on September 1, 2019. This event was filed by Halozyme Therapeutics Inc with SEC on 2009-05-08. Statement of changes in beneficial ownership - SEC Form 4
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio Architect